Method and apparatus for disconnecting the tip electrode during MRI

Information

  • Patent Grant
  • 8554335
  • Patent Number
    8,554,335
  • Date Filed
    Tuesday, July 19, 2011
    13 years ago
  • Date Issued
    Tuesday, October 8, 2013
    11 years ago
Abstract
A medical device includes a pulse generator, a lead, and an electrode. The lead includes an electrode and a lead conductor connecting the pulse generator with the electrode via first and second conductive paths. The medical device includes first and second switches. The first switch is disposed along the first conductive path and includes an open state in the presence of a magnetic field and a closed state in the absence of the magnetic field. The second switch is disposed along the second conductive path and includes an open state when a voltage applied across the second switch is at or below a threshold voltage and a closed state when the voltage applied across the second switch exceeds a threshold voltage.
Description
TECHNICAL FIELD

Embodiments of the present invention relate to medical devices and the simultaneous delivery of diagnostic and therapeutic treatments. More specifically, embodiments of the present invention relate to devices and methods for delivering cardiovascular diagnostic, pacing therapy in a magnetic field environment, or Tachy shock therapy.


BACKGROUND

Magnetic resonance imaging (MRI) is a non-invasive imaging method that utilizes nuclear magnetic resonance techniques to render images within a patient's body. Typically, MRI systems employ the use of a magnetic coil having a magnetic field strength of between about 0.2 to 3 Teslas. During the procedure, the body tissue is briefly exposed to RF pulses of electromagnetic energy in a plane perpendicular to the magnetic field. The resultant electromagnetic energy from these pulses can be used to image the body tissue by measuring the relaxation properties of the excited atomic nuclei in the tissue.


During imaging, the electromagnetic radiation produced by the MRI system may be picked up by implantable device leads used in implantable medical devices such as pacemakers or cardiac defibrillators. This energy may be transferred through the lead to the electrode in contact with the tissue, which may lead to elevated temperatures at the point of contact. The degree of tissue heating is typically related to factors such as the length of the lead, the properties of the tissue near the lead, the conductivity or impedance of the lead, the shape of the lead, and the surface area of the lead electrodes. Exposure to a magnetic field may also induce an undesired voltage in the lead.


SUMMARY

A medical device includes a pulse generator, a lead, and an electrode. The lead includes an electrode and a lead conductor connecting the pulse generator with the electrode via first and second conductive paths. The medical device includes first and second switches. The first switch is disposed along the first conductive path and includes an open state in the presence of a magnetic field and a closed state in the absence of the magnetic field. The second switch is disposed along the second conductive path and includes an open state when a voltage applied across the second switch is at or below a threshold voltage and a closed state when the voltage applied across the second switch exceeds a threshold voltage.


While some embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic drawing of an example cardiac rhythm management system including a pulse generator coupled to a lead deployed in a patient's heart.



FIG. 2A illustrates an MRI electrode isolation device between a lead conductor and an electrode.



FIG. 2B illustrates an alternative configuration of the MRI electrode isolation device between the lead conductor and the electrode.



FIG. 3 illustrates a pulse generator with a lead having an electrode separated from the lead conductor by a magnetoresistive element with a bypass circuit.



FIG. 4 is a chart which illustrates pacing voltage pulse magnitudes in both the normal mode and the MRI mode.



FIG. 5A illustrates a pulse generator and a lead with an enlarged view of a hermetically sealed reed switch and double Zener bypass.



FIG. 5B illustrates an alternative configuration of the pulse generator and the lead with the enlarged view of the hermetically sealed reed switch and double Zener bypass.



FIG. 6 illustrates a pulse generator with a lead and a magnetoresistive material or reed switch separating the lead conductor and the electrode along with a bypass switch.



FIG. 7 illustrates a pulse generator with a lead and a magnetoresistive material or reed switch separating the lead conductor and the electrode along with a bypass switch.



FIG. 8 is an example process for detecting a magnetic field and establishing conductive paths between the pulse generator and the electrode.





While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the present disclosure.


DETAILED DESCRIPTION


FIG. 1 is a schematic drawing of a cardiac rhythm management system 10 including a pulse generator 12 coupled to a lead 14 deployed in a patient's heart 16. As is known in the art, the pulse generator 12 is typically implanted subcutaneously at an implantation location in the patient's chest or abdomen. As shown, the heart 16 includes a superior vena cava 17, a right atrium 18 and a right ventricle 20, a left atrium 22 and a left ventricle 24, a coronary sinus ostium 26, a coronary sinus 28, and various cardiac branch vessels including a great cardiac vein 30 and an exemplary branch vessel 32.


In the embodiment of FIG. 1, the lead 14 may include an elongated body 34 having a proximal region 36 and a distal region 38. The distal region 38 has a distal end 40 including an electrode 42. The lead 14 includes a lead conductor which electrically connects the pulse generator 12 to the electrode 42. To facilitate left ventricular pacing epicardially via an epicardial approach, the lead 14 may be deployed in coronary veins 32 through the coronary sinus 28. In embodiments, the lead 14 can be implanted in other locations of the body such as the right ventricle 20, right atrium 18, or any other desired location in the body. Although FIG. 1 depicts the lead 14 as part of a cardiac rhythm management system 10 with an electrode 42, the lead 14 may alternatively include one or more sensors and/or one or more electrodes 42, and may couple the one or more sensors or electrodes 42 with a monitor in addition to, or in lieu of, the pulse generator 12. Additionally, although only one lead is illustrated in FIG. 1, the cardiac management system 10 may include any desired number of leads.


In embodiments, the pulse generator 12 is configured to emit therapy pulses such as pacing pulses for cardiovascular therapy or pulses for shock therapy. Examples of therapy pulses include, but are not limited to, cardiac pacing pulses for heart failure and bradycardia; anti-tachy pacing and shock therapy for tachycardia; and pacing pulses for neurostimulation and pain mitigation. In embodiments, the pulse generator 12 operates in a normal mode in the absence of a magnetic field and an MRI mode in the presence of the magnetic field generated during MRI imaging. In embodiments, the pulse generator 12 includes one or more sensors to detect the presence of the magnetic field. In some embodiments, the pulse generator 12 is communicable with a remote device that switches the pulse generator 12 between the normal and MRI modes. In other embodiments, the pulse generator 12 detects the presence of a magnetic field by measuring the lead impedance of the lead conductor of lead 14.


In some embodiments, and as discussed further herein, when the pulse generator 12 is operating in the normal mode, the pulse generator 12 emits pacing pulses at a specified voltage level. When the pulse generator 12 is operating in the MRI mode, the pulse generator 12 emits pacing pulses at the specified voltage level plus a threshold voltage. In embodiments, the pulse generator 12 operates in the MRI mode only upon detection of the magnetic field. Generally, the pulse generator 12 is in the presence of the magnetic field for a minimal portion of the life time of the battery of the pulse generator 12. Accordingly, configuring the pulse generator 12 to operate in the MRI mode only when needed or in the presence of a magnetic field conserves the battery power of the pulse generator 12 since the pulse generator 12 operating in the MRI mode may consume more battery power compared to operating in the normal mode.



FIG. 2A illustrates an MRI electrode isolation device 44 between a lead 14 and an electrode 42, according to embodiments of the present invention. In embodiments, the isolation device 44 is used to isolate the electrode (and thus surrounding tissue) from electromagnetic radiation, induced currents or voltages caused by the MRI procedure, and/or interaction with the elongated lead 14 conductors.


In embodiments, the device 44 includes a magnetic switch 48. In embodiments, the magnetic switch 48 is a single-pole double throw switch such as a reed switch. In the absence of any magnetic field, the switch 48, which is normally closed, shorts the lead conductor and the electrode at node 50 to conserve energy. In the presence of a magnetic field of the magnitude typically observed in an MRI procedure, such as the static magnetic field represented by arrow 46 of FIG. 2A, the switch 48 opens and redirects the circuit path through node 52 and through a relay control switch 54. In embodiments, the relay control switch 54 is normally open to isolate the electrode (and thus surrounding tissue) from the elongated lead 14 conductor, electromagnetic radiation and/or induced currents or voltages caused by the MRI procedure. Further, in embodiments, the relay control switch 54 is configured to close the circuit between the lead conductor and the electrode 42 during the delivery of required therapy (e.g. a pacing pulse), according to some embodiments.


According to some embodiments, the relay control switch 54 includes a relay control 55 that monitors the voltage across the switch 54 and closes the switch 54 when a certain threshold voltage level has been exceeded. According to embodiments, the therapy voltage provided by the pulse generator 12, when operating in the MRI mode, exceeds the threshold voltage level across the relay control switch 54, and the relay control switch 54 closes during the therapy pulse, which establishes a conductive path between the pulse generator 12 and lead 14 and electrode 42 via node 52. In some embodiments, the relay control 55 utilizes lines 56 and 57 to determine the voltage across switch 54 by measuring the voltage potential between node 51B and the electrode 42. If this voltage potential exceeds the threshold, the relay control 55 triggers the closure of the relay control switch 54. According to other embodiments, the pulse generator 12 is configured to send a control signal via line 58 timed to coincide with a therapy pulse, in order to trigger closure of the relay control switch 54 during the therapy pulse.


The magnetic switch 48 may be a mechanical switch according to embodiments. In some embodiments, the switch 48 can monitor a signal from a magnetic field detector and/or sensor and change the state of the switch 48 upon detection of a magnetic field 46. Alternatively, and in other embodiments, the switch 48 itself may be sensitive to the magnetic field. As an example, the switch 48 may be a reed switch, in which the magnetic field 46 itself moves the pole from the position shown in FIG. 2A in solid lines (arrow 51A connected to node 50) to the position shown in FIG. 2A in dashed lines (arrow 51B connected to node 52).



FIG. 2B illustrates an alternative configuration of the MRI electrode isolation device between the lead conductor and the electrode. As illustrated in FIG. 2B, the relay control switch 54 is directly connected to the lead 14 via line 59. In embodiments, the line 59 is an extension of the lead 14 providing a connection between the lead 14 and the relay control switch 54. Accordingly, in this configuration, in the absence of the magnetic field 46, the switch 48 shorts the lead 14 and the electrode 42 at node 50. In the presence of the magnetic field 46, the pole of switch 48 moves from node 50 to node 52 disconnecting the lead 14 from the electrode 42. In the presence of the magnetic field 46, during delivery of a therapy pulse, the pulse generator 12 sends a signal to the relay control 55 via line 58 to close the switch 54. Accordingly, therapy pulses sent from the pulse generator 12 along lead 14 reach the electrode via line 59 and the relay control switch 54.



FIG. 3 illustrates a pulse generator 12 with a lead 14 having an electrode 42 separated from the lead conductor by a magnetoresistive element 60 with a bypass circuit 62, according to embodiments of the present invention. The magnetoresistive element 60 may be, for example, ballistic magnetoresistive (“BMR”) material which greatly increases the resistance between the lead conductor and the electrode 42 in the presence of a static magnetic field produced by an MRI scanner. According to some embodiments, the resistance created by the magnetoresistive element 60 in the presence of an MRI static magnetic field is large enough to prevent formation of the conductive path between the pulse generator 12 and the electrode 42 via the magnetoresistive element 60. Alternatively, and in other embodiments, the magnetoresistive element 60 may be a magnetic switch as described above with respect to FIGS. 2A and 2B.


A bypass device 62 may be used to bypass the magnetoresistive element 60 in the presence of a magnetic field. The bypass device 62 may be an electrical or mechanical threshold circuit, such as, for example, a Zener diode, back-to-back Zener diodes, or devices with similar characteristics. According to some embodiments, the bypass device 62 features an open circuit or a high resistance until a voltage applied across the device 62 exceeds a threshold voltage. In embodiments, the pulse generator 12, when operating in the MRI mode, is configured to deliver a pacing pulse with a voltage level that exceeds the threshold voltage of the device 62.



FIG. 4 is a chart which illustrates pacing voltage pulse magnitudes verses time in both the normal mode and the MRI mode. In the normal mode when an MRI magnetic field is not present, the pulse generator 12 may supply pacing pulses of a certain magnitude, as shown on the left side of FIG. 4. In the MRI mode when the MRI magnetic field is detected, the pulse generator 12 supplies pacing pulses of a magnitude equal to the normal magnitude plus a threshold voltage, as shown on the right side of FIG. 4. In embodiments, the pacing pulse+Vth is sufficient to override the bypass device 62 permitting a conductive path between the pulse generator 12 and the electrode 42. In embodiments, the Vth is removed from the pacing pulse by the bypass device 62 to provide a pacing pulse of normal voltage level to the electrode 42 and surrounding tissue. Accordingly, the pacing pulse+Vth in the MRI mode permits the pacing pulse to override the bypass device 62 with the threshold voltage level and permits delivery of a pacing pulse of normal magnitude to the electrode 42.


In embodiments, the duration of pacing pulses and signals emitted from the pulse generator 12 are longer than a threshold duration, which means that the frequency of the pacing pulses is not higher than a threshold frequency (e.g., frequency=1/duration). In some embodiments, the threshold duration is 60 nanoseconds and the threshold frequency is 8.5 MHz. In embodiments, any switch, controller, or device that receives pacing pulses or signals from the pulse generator 12 is responsive to pacing pulses or signals below a particular frequency. As an example, the bypass device 62 (FIG. 3) closes upon receiving one or more pacing pulses from the pulse generator 12 that are above the threshold voltage and have a duration longer than the threshold duration.



FIG. 5A illustrates a pulse generator 12 and a lead 14 implanted within the heart 16, with an enlarged view of a hermetically sealed reed switch 64 and double Zener bypass 70, according to embodiments of the present invention. In embodiments, the switch 64 includes a pole 66, a non-ferromagnetic contact 68, and a ferromagnetic contact 69. The pole 66 of the switch 64, which is in electrical communication with the lead conductor of the lead 14, may be constructed with a ferromagnetic material. In further embodiments, the pole 66 is elastic. In the absence of a magnetic field, the pole 66 is in a non-expanded state (e.g. relaxed state) and keeps in contact with the non-ferromagnetic contact 68. When applying a magnetic field to the switch 64, such as that applied during an MRI procedure, the ferromagnetic pole 66 is attracted to the ferromagnetic contact 69. Accordingly, in the presence of the magnetic field, the attraction between the pole 66 and the ferromagnetic contact 69 causes the pole 66 to move towards the ferromagnetic contact 69. Thus, in the presence of the magnetic field, the pole 66 is deflected from the position shown in FIG. 5A in solid lines in which the lead conductor is shorted to the electrode 42 to the position shown in FIG. 5A in dashed lines in which a back-to-back Zener diode 70 separates the lead conductor from the electrode 42.


The diode 70 may be used to override the switch 64 during therapy. In embodiments, the pulse generator 12, when operating in the MRI mode, is configured to deliver a pacing pulse such as the pacing pulse illustrated in FIG. 4 with a voltage level high enough to override the back-to-back Zener diode 70.



FIG. 5B illustrates an alternative configuration of the pulse generator 12 and the lead 14 with the enlarged view of the hermetically sealed reed switch 64 and double Zener bypass 70. The double Zener bypass 70 is directly connected to the lead 14 via line 71. In embodiments, the line 71 is an extension of the lead 14 providing a connection between the lead 14 and the double Zener bypass 70. Accordingly, in this configuration, in the absence of a magnetic field, the pole 66 is in a non-expanded state and keeps in contact with the non-ferromagnetic contact 68. In the presence of the magnetic field, the attraction between the pole 66 and the ferromagnetic contact 69 causes the pole 66 to move towards the ferromagnetic contact 69, which disconnects the lead 14 from the electrode 42. When operating in the MRI mode in the presence of the magnetic field, the pulse generator 12 is configured to emit a therapy pulse with a voltage level high enough to override the back-to-back Zener diode 70 providing a conductive path between the pulse generator 12 and the electrode 42.



FIG. 6 illustrates a pulse generator 12 with a lead 14 and a magnetoresistive element 60 separating the lead conductor and the electrode 42 along with a bypass switch 72. In other embodiments a reed switch separates the lead conductor from the electrode 42. As shown in FIG. 6, the bypass switch 72 is electronically controlled by the pulse generator 12 via a control line 74. In the presence of a magnetic field, the magnetoresistive element 60 changes from a low impedance state to a high impedance state, and substantially electrically isolates the lead conductor of the lead 14 from the electrode 42. A signal sent from the pulse generator 12 to the bypass switch 72 through the control line 74 bypasses the magnetoresistive element 60 during the delivery of therapy pulses. In some embodiments, the bypass signal from the pulse generator 12 is sent through control line 74 to bypass switch 72 during a therapy pulse only when the pulse generator 12 is operating in the MRI mode in order to conserve the battery power of the pulse generator 12. Alternatively, and in other embodiments, the bypass signal from the pulse generator 12 may be sent through control line 74 to bypass switch 72 at other times such as immediately prior to delivering a therapeutic pulse. In embodiments, the control line 74 is a fiber optic line and the switch 72 is an optical switch.



FIG. 7 illustrates a pulse generator 12 with a lead 14 and a magnetoresistive element 60 separating the lead conductor and the electrode 42 along with a bypass switch 76. In other embodiments a reed switch separates the lead conductor from the electrode 42. As shown in FIG. 7, the bypass switch 76 is optically controlled by the pulse generator 12 via a fiber optic line 78 located within the lead 14. In embodiments, the fiber optic line 78 may be contained within the lead 14 and connects the pulse generator 12 to the magnetoresistive element. In embodiments, the lead 14 connects the pulse generator 12 to the bypass switch 76.


In the presence of a magnetic field, the magnetoresistive element 60 changes from a low impedance state to a high impedance state, and substantially electrically isolates the lead conductor of the lead 14 from the electrode 42. In embodiments, when the pulse generator 12 is operating in the MRI mode, a signal sent from the pulse generator 12 to the bypass switch 76 via the fiber optic line 78 bypasses the magnetoresistive element 60 during the delivery of therapeutic pulses. Accordingly, while in the MRI mode, the pulse generator 12 activates the bypass switch 76 via fiber optic line 78 to permit therapy pulses to reach the electrode 42 via lead 14. In some embodiments, the bypass signal from the pulse generator 12 is sent through the line 78 to bypass switch 76 during a therapy pulse only when the pulse generator 12 is operating in the MRI mode in order to minimize energy use. By activating the bypass switches 72, 76 only in an MRI environment (e.g., when the pulse generator 12 is operating in an MRI mode) and only during delivery of therapy, the pulse generator 12 may conserve battery power usage.



FIG. 8 is an example process for detecting a magnetic field and establishing conductive paths between the pulse generator and the electrode. In some embodiments, the process illustrated in FIG. 8 may be applicable to the embodiments disclosed in FIGS. 2, 3, and 5-7. For illustrative purposes, the description of the process in FIG. 8 is made with respect to the embodiment illustrated in FIG. 2A where the single-pole double throw magnetic switch 48 is a first switch, and the relay switch 54 is a second switch.


The process in FIG. 8 may generally begin at block 90 where the pulse generator 12 determines if a magnetic field is detected. In embodiments, the magnetic field can be detected by using a Hall effect, reed switch, magnetoresistive material such as Giant Magneto Resistance (GMR) or BMR, or other suitable sensors. If no magnetic field is detected, the pulse generator 12 operates in the normal mode (block 92). Further, when the pulse generator 12 is operating in normal mode the conductive path between the pulse generator 12 and electrode is established via the first switch (block 94). In embodiments, in the absence of the magnetic field, the magnetic switch 48 connects the pole to the node 50 to create a conductive path between the pulse generator 12 and the electrode 42. When the conductive path between the pulse generator 12 and the electrode 42 via the first switch 48 is established 94, the pulse generator 12 returns to determining if a magnetic field is detected (block 90).


If a magnetic field is detected, the pulse generator 12 operates in the MRI mode (block 96). Further, when the magnetic field is detected, the conductive path provided between the pulse generator 12 and the electrode via the first switch 48 is substantially prevented (block 98). In embodiments, in the presence of the magnetic field, the single-pole of the magnetic switch 48 deflects from node 50 to node 52. Additionally, the second switch 54 monitors a voltage (V) across the second switch (block 100). In certain embodiments, for example, the second switch 54 may monitor a voltage (V) provided by the pulse generator 12. In embodiments, the relay switch 54 monitors the voltage applied across the second switch 54.


After measuring the voltage (V), the second switch 54 determines if the measured voltage (V) is greater than the voltage threshold (Vth) of the second switch 54 (block 102). If V≦Vth, the second switch 54 determines if the second switch 54 is closed (block 104), then the second switch 54 is opened (block 106). In embodiments, the second switch 54 is opened when V≦Vth. If the second switch 54 is already opened 104, the process returns to determining if the magnetic field is still present (block 90).


If V>Vth (block 102), the second switch 54 determines if the second switch 54 is closed (block 108). If the second switch 54 determines that the second switch 54 is open, the second switch 54 is then closed (block 110). In embodiments, the second switch 54 is closed when V>Vth. If the second switch 54 is already closed (block 108), the pulse generator 12 returns to determining if the magnetic field is still present (block 90).


Although several embodiments are disclosed with respect to a cardiac management system 10 deployed in a patient's heart 16 (FIG. 1), the several embodiments are applicable to any system deployed in a patient's body that may be subject to an MRI scan. As an example, the several embodiments are applicable to neuromodulation devices with one or more leads that come into contact with human tissue.


Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the present disclosure, together with all equivalents thereof.

Claims
  • 1. An electrode isolation device for electrically isolating an electrode of an implantable lead in the presence of a magnetic field, the implantable lead including a lead conductor configured to connect the electrode to a pulse generator via first and second conductive paths, the electrode isolation device comprising: a first switch coupled between the pulse generator and the electrode along the first conductive path, the first switch including an open state in the presence of the magnetic field that electrically disconnects the first conductive path between the pulse generator and the electrode, the first switch further including a closed state in the absence of the MRI magnetic field that electrically connects the first conductive path between the pulse generator and the electrode; anda second switch coupled between the pulse generator and the electrode along the second conductive path, the second switch including an open state that electrically disconnects the first conductive path between the pulse generator and the electrode, the second switch further including a closed state that electrically connects the second conductive path between the pulse generator and the electrode when a voltage applied across the second switch exceeds a threshold voltage.
  • 2. The electrode isolation device of claim 1, wherein the first switch is a single-pole double-throw magnetic switch, wherein in the absence of the magnetic field, the single-pole double-throw magnetic switch is closed, and wherein in the presence of the MRI magnetic field, the single-pole double-throw magnetic switch is open.
  • 3. The electrode isolation device of claim 2, wherein the single-pole double-throw magnetic switch is a reed switch.
  • 4. The electrode isolation device of claim 1, wherein the first switch comprises magnetoresistive material.
  • 5. The electrode isolation device of claim 1, wherein the second switch further comprises a Zener diode bypass.
  • 6. The electrode isolation device of claim 1, wherein the second switch is a voltage controlled switch configured to short the lead conductor to the electrode when the voltage applied across the second switch exceeds a predetermined threshold voltage.
  • 7. The electrode isolation device of claim 1, wherein the second switch is in the closed state when the voltage applied across the second switch exceeds the threshold voltage and exceeds a threshold duration.
  • 8. The electrode isolation device of claim 1, wherein the second switch receives a signal via a control line from the pulse generator, and wherein the signal directs the second switch to the closed state during therapy signals from the pulse generator.
  • 9. A method for selectively connecting a pulse generator and an electrode, the method comprising: controlling a state of a first switch coupled along a first conductive path between the pulse generator and the electrode such that, in the absence of a magnetic field, the first switch is closed to electrically connect the pulse generator and the electrode via the first conductive path, and in the presence of the magnetic field, the first switch is open to electrically disconnect the first conductive path between the pulse generator and the electrode; andcontrolling a state of a second switch coupled along a second conductive path between the pulse generator and the electrode such that the second switch is open to electrically disconnect the second conductive path between the pulse generator and the electrode when a voltage applied across the second switch is less than or equal to a threshold voltage, and second switch is closed to electrically connect the pulse generator and the electrode via the second conductive path when the voltage applied across the second switch is greater than the threshold voltage.
  • 10. The method of claim 9, wherein the first switch is a single-pole double-throw magnetic switch, wherein in the absence of the magnetic field, the single-pole double-throw magnetic switch closes the first conductive path between the pulse generator and the electrode, and wherein in the presence of the magnetic field, the single-pole double-throw magnetic switch connects the pulse generator to the second switch.
  • 11. The method of claim 10, wherein the single-pole double-throw magnetic switch is a reed switch.
  • 12. The method of claim 9, wherein the first switch comprises magnetoresistive material.
  • 13. The method of claim 9, wherein the second switch further comprises a Zener diode bypass.
  • 14. The method of claim 9, wherein the second switch is a voltage controlled switch configured to short the lead conductor to the electrode when the detected voltage exceeds the threshold voltage.
  • 15. The method of claim 9, wherein the pulse generator delivers one or more therapy signals that exceed the threshold voltage when the pulse generator is operating in an MRI mode.
  • 16. The method of claim 9, wherein controlling the state of the second switch further comprises: closing the second switch to electrically connect the pulse generator and the electrode via the second conductive path when the voltage applied across the second switch is greater than the threshold voltage and exceeds a threshold duration.
  • 17. The method of claim 9, further comprising receiving a signal at the second switch via a control line from the pulse generator, the signal directing the second switch close during a therapy pulse from the pulse generator.
  • 18. A method for delivering therapy from a pulse generator to an electrode, the pulse generator connected to the electrode via first and second conductive paths, comprising: delivering one or more therapy signals at a first voltage level when the pulse generator is operating in a normal mode in the absence of a magnetic field, the one or more therapy signals at the first voltage level reaching the electrode via the first conductive path; anddelivering one or more therapy signals from the pulse generator at a second voltage level when the pulse generator is operating in an MRI mode in the presence of the magnetic field, the second voltage level greater than the first voltage level, the one or more therapy signals from the pulse generator at the second voltage level reaching the electrode via the second conductive path.
  • 19. The method of claim 18, wherein the one or more therapy signals at the second voltage level exceed a threshold voltage of a switch positioned between the pulse generator and the electrode via the second conductive path.
  • 20. The method of claim 18, wherein the one or more therapy signals are delivered via the second conductive path when the one or more therapy signals exceed the threshold voltage and exceed a threshold duration.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/329,383, filed Dec. 5, 2008, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent No. 60/992,991, filed on Dec. 6, 2007, each of which is incorporated herein by reference in its entirety.

US Referenced Citations (336)
Number Name Date Kind
3888260 Fischell Jun 1975 A
3898995 Dresbach Aug 1975 A
4091818 Brownlee et al. May 1978 A
4379459 Stein Apr 1983 A
4404125 Abolins et al. Sep 1983 A
4516579 Irnich May 1985 A
4611127 Ibrahim et al. Sep 1986 A
4694837 Blakeley et al. Sep 1987 A
4729376 DeCote, Jr. Mar 1988 A
4751110 Gulla et al. Jun 1988 A
4779617 Whigham Oct 1988 A
4823075 Alley Apr 1989 A
4869970 Gulla et al. Sep 1989 A
4934366 Truex et al. Jun 1990 A
5038785 Blakeley et al. Aug 1991 A
5075039 Goldberg Dec 1991 A
5076841 Chen et al. Dec 1991 A
5120578 Chen et al. Jun 1992 A
5181511 Nickolls et al. Jan 1993 A
5187136 Klobucar et al. Feb 1993 A
5188117 Steinhaus et al. Feb 1993 A
5197468 Proctor et al. Mar 1993 A
5217010 Tsitlik et al. Jun 1993 A
5243911 Dow et al. Sep 1993 A
5279225 Dow et al. Jan 1994 A
5288313 Portner Feb 1994 A
5292342 Nelson et al. Mar 1994 A
5309096 Hoegnelid May 1994 A
5325728 Zimmerman et al. Jul 1994 A
5345362 Winkler Sep 1994 A
5391188 Nelson et al. Feb 1995 A
5406444 Selfried et al. Apr 1995 A
5424642 Ekwall Jun 1995 A
5438900 Sundstrom Aug 1995 A
5454837 Lindegren et al. Oct 1995 A
5470345 Hassler et al. Nov 1995 A
5523578 Herskovic Jun 1996 A
5527348 Winkler et al. Jun 1996 A
5529578 Struble Jun 1996 A
5545187 Bergstrom et al. Aug 1996 A
5562714 Grevious Oct 1996 A
5607458 Causey, III et al. Mar 1997 A
5609622 Soukup et al. Mar 1997 A
5618208 Crouse et al. Apr 1997 A
5620476 Truex et al. Apr 1997 A
5647379 Meltzer Jul 1997 A
5649965 Pons et al. Jul 1997 A
5650759 Hittman et al. Jul 1997 A
5662694 Lidman et al. Sep 1997 A
5662697 Li et al. Sep 1997 A
5683434 Archer Nov 1997 A
5687735 Forbes et al. Nov 1997 A
5694952 Lidman et al. Dec 1997 A
5697958 Paul et al. Dec 1997 A
5709225 Budgifvars et al. Jan 1998 A
5714536 Ziolo et al. Feb 1998 A
5722998 Prutchi et al. Mar 1998 A
5727552 Ryan Mar 1998 A
5735884 Thompson et al. Apr 1998 A
5749910 Brumwell et al. May 1998 A
5751539 Stevenson et al. May 1998 A
5759197 Sawchuk et al. Jun 1998 A
5764052 Renger Jun 1998 A
5766227 Nappholz et al. Jun 1998 A
5776168 Gunderson Jul 1998 A
5782241 Felblinger et al. Jul 1998 A
5782891 Hassler et al. Jul 1998 A
5792201 Causey, III et al. Aug 1998 A
5800496 Swoyer et al. Sep 1998 A
5800497 Bakels et al. Sep 1998 A
5814090 Latterell et al. Sep 1998 A
5817130 Cox et al. Oct 1998 A
5827997 Chung et al. Oct 1998 A
5853375 Orr Dec 1998 A
5867361 Wolf et al. Feb 1999 A
5869078 Baudino Feb 1999 A
5870272 Seifried et al. Feb 1999 A
5871509 Noren Feb 1999 A
5877630 Kraz Mar 1999 A
5895980 Thompson Apr 1999 A
5905627 Brendel et al. May 1999 A
5959829 Stevenson et al. Sep 1999 A
5964705 Truwit et al. Oct 1999 A
5968854 Akopian et al. Oct 1999 A
5973906 Stevenson et al. Oct 1999 A
5978204 Stevenson Nov 1999 A
5978710 Prutchi et al. Nov 1999 A
5999398 Makl et al. Dec 1999 A
6008980 Stevenson et al. Dec 1999 A
6031710 Wolf et al. Feb 2000 A
6032063 Hoar et al. Feb 2000 A
6055455 O'Phelan et al. Apr 2000 A
6079681 Stern et al. Jun 2000 A
6101417 Vogel et al. Aug 2000 A
6147301 Bhatia Nov 2000 A
6161046 Maniglia et al. Dec 2000 A
6162180 Miesel et al. Dec 2000 A
6173203 Barkley et al. Jan 2001 B1
6188926 Vock Feb 2001 B1
6192279 Barreras, Sr. et al. Feb 2001 B1
6198968 Prutchi et al. Mar 2001 B1
6198972 Hartlaub et al. Mar 2001 B1
6209764 Hartlaub et al. Apr 2001 B1
6217800 Hayward Apr 2001 B1
6235038 Hunter et al. May 2001 B1
6245464 Spillman et al. Jun 2001 B1
6246902 Naylor et al. Jun 2001 B1
6249701 Rajasekhar et al. Jun 2001 B1
6268725 Vernon et al. Jul 2001 B1
6270831 Kumar et al. Aug 2001 B2
6275369 Stevenson et al. Aug 2001 B1
6288344 Youker et al. Sep 2001 B1
6324431 Zarinetchi et al. Nov 2001 B1
6358281 Berrang et al. Mar 2002 B1
6365076 Bhatia Apr 2002 B1
6381494 Gilkerson et al. Apr 2002 B1
6421555 Nappholz Jul 2002 B1
6424234 Stevenson Jul 2002 B1
6446512 Zimmerman et al. Sep 2002 B2
6452564 Schoen et al. Sep 2002 B1
6456481 Stevenson Sep 2002 B1
6459935 Piersma Oct 2002 B1
6470212 Weijand et al. Oct 2002 B1
6487452 Legay Nov 2002 B2
6490148 Allen et al. Dec 2002 B1
6496714 Weiss et al. Dec 2002 B1
6503964 Smith et al. Jan 2003 B2
6506972 Wang Jan 2003 B1
6510345 Van Bentem Jan 2003 B1
6512666 Duva Jan 2003 B1
6522920 Silvian et al. Feb 2003 B2
6526321 Spehr Feb 2003 B1
6539253 Thompson et al. Mar 2003 B2
6545854 Trinh et al. Apr 2003 B2
6555745 Kruse et al. Apr 2003 B1
6563132 Talroze et al. May 2003 B1
6566978 Stevenson et al. May 2003 B2
6567259 Stevenson et al. May 2003 B2
6580947 Thompson Jun 2003 B1
6584351 Ekwall Jun 2003 B1
6595756 Gray et al. Jul 2003 B2
6607485 Bardy Aug 2003 B2
6626937 Cox Sep 2003 B1
6629938 Engvall et al. Oct 2003 B1
6631290 Guck et al. Oct 2003 B1
6631555 Youker et al. Oct 2003 B1
6640137 MacDonald Oct 2003 B2
6643903 Stevenson et al. Nov 2003 B2
6646198 Maciver et al. Nov 2003 B2
6648914 Berrang et al. Nov 2003 B2
6662049 Miller Dec 2003 B1
6673999 Wang et al. Jan 2004 B1
6711440 Deal et al. Mar 2004 B2
6713671 Wang et al. Mar 2004 B1
6718203 Weiner et al. Apr 2004 B2
6718207 Connelly Apr 2004 B2
6725092 MacDonald et al. Apr 2004 B2
6731979 MacDonald May 2004 B2
6795730 Connelly et al. Sep 2004 B2
6901292 Hrdlicka et al. May 2005 B2
6925328 Foster et al. Aug 2005 B2
6937906 Terry et al. Aug 2005 B2
6944489 Zeijlemaker et al. Sep 2005 B2
6963779 Shankar Nov 2005 B1
7013180 Dublin et al. Mar 2006 B2
7020517 Weiner Mar 2006 B2
7050855 Zeijlemaker et al. May 2006 B2
7076283 Cho et al. Jul 2006 B2
7082328 Funke Jul 2006 B2
7092756 Zhang et al. Aug 2006 B2
7123013 Gray Oct 2006 B2
7138582 Lessar et al. Nov 2006 B2
7164950 Kroll et al. Jan 2007 B2
7174219 Wahlstrand et al. Feb 2007 B2
7174220 Chitre et al. Feb 2007 B1
7212863 Strandberg May 2007 B2
7231251 Yonce et al. Jun 2007 B2
7242981 Ginggen Jul 2007 B2
7272444 Peterson et al. Sep 2007 B2
7369898 Kroll et al. May 2008 B1
7388378 Gray et al. Jun 2008 B2
7509167 Stessman Mar 2009 B2
7561915 Cooke et al. Jul 2009 B1
7801625 MacDonald Sep 2010 B2
7835803 Malinowski et al. Nov 2010 B1
7839146 Gray Nov 2010 B2
8014867 Cooke et al. Sep 2011 B2
8032228 Ameri et al. Oct 2011 B2
8086321 Ameri Dec 2011 B2
8121705 MacDonald Feb 2012 B2
8160717 Ameri Apr 2012 B2
8311637 Ameri Nov 2012 B2
20010002000 Kumar et al. May 2001 A1
20010006263 Hayward Jul 2001 A1
20010011175 Hunter et al. Aug 2001 A1
20010018123 Furumori et al. Aug 2001 A1
20010025139 Pearlman Sep 2001 A1
20010037134 Munshi Nov 2001 A1
20010050837 Stevenson et al. Dec 2001 A1
20020019658 Munshi Feb 2002 A1
20020026224 Thompson et al. Feb 2002 A1
20020038135 Connelly et al. Mar 2002 A1
20020050401 Youker et al. May 2002 A1
20020072769 Silvian et al. Jun 2002 A1
20020082648 Kramer et al. Jun 2002 A1
20020102835 Stucchi et al. Aug 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020117314 Maciver et al. Aug 2002 A1
20020128689 Connelly et al. Sep 2002 A1
20020128691 Connelly Sep 2002 A1
20020133086 Connelly et al. Sep 2002 A1
20020133199 MacDonald et al. Sep 2002 A1
20020133200 Weiner et al. Sep 2002 A1
20020133201 Connelly et al. Sep 2002 A1
20020133202 Connelly et al. Sep 2002 A1
20020133208 Connelly Sep 2002 A1
20020133211 Weiner et al. Sep 2002 A1
20020133216 Connelly et al. Sep 2002 A1
20020138102 Weiner et al. Sep 2002 A1
20020138107 Weiner et al. Sep 2002 A1
20020138108 Weiner et al. Sep 2002 A1
20020138110 Connelly et al. Sep 2002 A1
20020138112 Connelly et al. Sep 2002 A1
20020138113 Connelly et al. Sep 2002 A1
20020138124 Helfer et al. Sep 2002 A1
20020143258 Weiner et al. Oct 2002 A1
20020147388 Mass et al. Oct 2002 A1
20020147470 Weiner et al. Oct 2002 A1
20020162605 Horton et al. Nov 2002 A1
20020166618 Wolf et al. Nov 2002 A1
20020175782 Trinh et al. Nov 2002 A1
20020183796 Connelly Dec 2002 A1
20020198569 Foster et al. Dec 2002 A1
20030036774 Maier et al. Feb 2003 A1
20030036776 Foster et al. Feb 2003 A1
20030045907 MacDonald Mar 2003 A1
20030053284 Stevenson et al. Mar 2003 A1
20030055457 MacDonald Mar 2003 A1
20030056820 MacDonald Mar 2003 A1
20030074029 Deno et al. Apr 2003 A1
20030081370 Haskell et al. May 2003 A1
20030083570 Cho et al. May 2003 A1
20030083723 Wilkinson et al. May 2003 A1
20030083726 Zeijlemaker et al. May 2003 A1
20030083728 Greatbatch et al. May 2003 A1
20030100925 Pape et al. May 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030111142 Horton et al. Jun 2003 A1
20030114897 Von Arx et al. Jun 2003 A1
20030114898 Von Arx et al. Jun 2003 A1
20030120197 Kaneko et al. Jun 2003 A1
20030130647 Gray et al. Jul 2003 A1
20030130700 Miller et al. Jul 2003 A1
20030130701 Miller Jul 2003 A1
20030130708 Von Arx et al. Jul 2003 A1
20030135114 Pacetti et al. Jul 2003 A1
20030135160 Gray et al. Jul 2003 A1
20030139096 Stevenson et al. Jul 2003 A1
20030140931 Zeijlemaker et al. Jul 2003 A1
20030144704 Terry et al. Jul 2003 A1
20030144705 Funke Jul 2003 A1
20030144706 Funke Jul 2003 A1
20030144716 Reinke et al. Jul 2003 A1
20030144717 Hagele Jul 2003 A1
20030144718 Zeijlemaker Jul 2003 A1
20030144719 Zeijlemaker Jul 2003 A1
20030144720 Villaseca et al. Jul 2003 A1
20030144721 Villaseca et al. Jul 2003 A1
20030149459 Von Arx et al. Aug 2003 A1
20030158584 Cates et al. Aug 2003 A1
20030176900 MacDonald Sep 2003 A1
20030179536 Stevenson et al. Sep 2003 A1
20030191505 Gryzwa et al. Oct 2003 A1
20030195570 Deal et al. Oct 2003 A1
20030199755 Halperin et al. Oct 2003 A1
20030204207 MacDonald et al. Oct 2003 A1
20030204215 Gunderson et al. Oct 2003 A1
20030204217 Greatbatch Oct 2003 A1
20030213604 Stevenson et al. Nov 2003 A1
20030213605 Brendel et al. Nov 2003 A1
20040005483 Lin Jan 2004 A1
20040015162 McGaffigan Jan 2004 A1
20040015197 Gunderson Jan 2004 A1
20040019273 Helfer et al. Jan 2004 A1
20040049237 Larson et al. Mar 2004 A1
20040088012 Kroll et al. May 2004 A1
20040093432 Luo et al. May 2004 A1
20040263174 Gray et al. Dec 2004 A1
20050043761 Connelly et al. Feb 2005 A1
20050070787 Zeijlemaker Mar 2005 A1
20050070975 Zeijlemaker et al. Mar 2005 A1
20050113676 Weiner et al. May 2005 A1
20050113873 Weiner et al. May 2005 A1
20050113876 Weiner et al. May 2005 A1
20050197677 Stevenson Sep 2005 A1
20050222656 Wahlstrand et al. Oct 2005 A1
20050222657 Wahlstrand et al. Oct 2005 A1
20050222658 Hoegh et al. Oct 2005 A1
20050222659 Olsen et al. Oct 2005 A1
20060025820 Phillips et al. Feb 2006 A1
20060030774 Gray et al. Feb 2006 A1
20060041294 Gray Feb 2006 A1
20060167496 Nelson et al. Jul 2006 A1
20060173295 Zeijlemaker Aug 2006 A1
20060247747 Olsen et al. Nov 2006 A1
20060247748 Wahlstrand et al. Nov 2006 A1
20060271138 MacDonald Nov 2006 A1
20060293591 Wahlstrand et al. Dec 2006 A1
20070019354 Kamath Jan 2007 A1
20070021814 Inman et al. Jan 2007 A1
20070179577 Marshall et al. Aug 2007 A1
20070179582 Marshall et al. Aug 2007 A1
20070191914 Stessman Aug 2007 A1
20070203523 Betzold Aug 2007 A1
20070238975 Zeijlemaker Oct 2007 A1
20070255332 Cabelka et al. Nov 2007 A1
20080033497 Bulkes et al. Feb 2008 A1
20080132985 Wedan et al. Jun 2008 A1
20080154342 Digby et al. Jun 2008 A1
20080221638 Wedan et al. Sep 2008 A1
20080234772 Shuros et al. Sep 2008 A1
20090138058 Cooke et al. May 2009 A1
20090149906 Ameri et al. Jun 2009 A1
20090149909 Ameri Jun 2009 A1
20090157146 Linder et al. Jun 2009 A1
20090204182 Ameri Aug 2009 A1
20090210025 Ameri Aug 2009 A1
20100087892 Stubbs et al. Apr 2010 A1
20100211123 Stubbs et al. Aug 2010 A1
20110137359 Stubbs et al. Jun 2011 A1
20110270338 Cooke et al. Nov 2011 A1
20120071941 Ameri Mar 2012 A1
20120253425 Yoon et al. Oct 2012 A1
Foreign Referenced Citations (53)
Number Date Country
0530006 Mar 1993 EP
0591334 Apr 1994 EP
0331959 Dec 1994 EP
0891786 Jan 1999 EP
0891207 Nov 1999 EP
0980105 Feb 2000 EP
0989623 Mar 2000 EP
0989624 Mar 2000 EP
1007132 Jun 2000 EP
1109180 Jun 2001 EP
1128764 Sep 2001 EP
0705621 Jan 2002 EP
1191556 Mar 2002 EP
1271579 Jan 2003 EP
0719570 Apr 2003 EP
1308971 May 2003 EP
1007140 Oct 2003 EP
1372782 Jan 2004 EP
0870517 Jun 2004 EP
1061849 Nov 2005 EP
1060762 Aug 2006 EP
0836413 Aug 2008 EP
WO9104069 Apr 1991 WO
WO9638200 Dec 1996 WO
WO9712645 Apr 1997 WO
WO0054953 Sep 2000 WO
WO0137286 May 2001 WO
WO0180940 Nov 2001 WO
WO0186774 Nov 2001 WO
WO02056761 Jul 2002 WO
WO02065895 Aug 2002 WO
WO02072004 Sep 2002 WO
WO02089665 Nov 2002 WO
WO02092161 Nov 2002 WO
WO03013199 Feb 2003 WO
WO03037399 May 2003 WO
WO03059445 Jul 2003 WO
WO03061755 Jul 2003 WO
WO03063952 Aug 2003 WO
WO03063954 Aug 2003 WO
WO03063955 Aug 2003 WO
WO03063956 Aug 2003 WO
WO03063958 Aug 2003 WO
WO03063962 Aug 2003 WO
WO03070098 Aug 2003 WO
WO03073449 Sep 2003 WO
WO03073450 Sep 2003 WO
WO03086538 Oct 2003 WO
WO03090846 Nov 2003 WO
WO03090854 Nov 2003 WO
WO03095022 Nov 2003 WO
WO03063946 Apr 2005 WO
WO2006124481 Nov 2006 WO
Non-Patent Literature Citations (12)
Entry
Dempsey Mary F. et al., “Investigation of the Factors Responsible for Burns During MRI”, Journal of Magnetic Resonance Imaging 2001:13:627-631.
File History for U.S. Appl. No. 11/015,807, filed Dec. 17, 2004.
International Search Report and Written Opinion issued in PCT/US2009/059093, mailed Dec. 29, 2009.
International Search Report and Written Opinion issued in PCT/US2009/068314, mailed Mar. 25, 2009, 14 pages.
Kerr, Martha, “Shock Rate Cut 70% With ICDs Programmed to First Deliver Antitachycardia Pacing: Results of the PainFREE Rx II Trial,” Medscape CRM News, May 21, 2003.
Luechinger, Roger et al., “In vivo heating of pacemaker leads during magnetic resonance imaging”, European Heart Journal 2005;26:376-383.
Schueler, et al., “MRI Compatibility and Visibility Assessment of Implantable Medical Devices”, Journal of Magnetic Resonance Imaging, 9:596-603 (1999).
Shellock FG, “Reference manual for magnetic resonance safety, implants, and devices”, pp. 136-139, 2008 ed. Los Angeles; Biomedical Research Publishing Group; 2008.
Shellock, Frank G. et al., “Cardiovascular catheters and accessories: ex vivo testing of ferromagnetism, heating, and artifacts associated with MRI”, Journal of Magnetic Resonance Imaging, Nov./Dec. 1998; 8:1338-1342.
Sweeney, Michael O. et al., Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock Therapies (PainFREE Rx II) Trial, American Heart Association, 2005.
Wilkoff, Bruce L. et al., “A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators Results From the Prospective Randomized Multicenter EMPIRIC Trial,” Journal of the American College of Cardiology vol. 48, No. 2, 2006. doi:10.1016/j.jacc.2006.03.037.
International Search Report and Written Opinion issued in PCT/US2010/053202, mailed Dec. 30, 2010, 12 pages.
Related Publications (1)
Number Date Country
20110276104 A1 Nov 2011 US
Provisional Applications (1)
Number Date Country
60992991 Dec 2007 US
Continuations (1)
Number Date Country
Parent 12329383 Dec 2008 US
Child 13186194 US